Last reviewed · How we verify
OSI-930 and erlotinib
OSI-930 and erlotinib is a Small molecule drug developed by Astellas Pharma Inc. It is currently in Phase 1 development.
At a glance
| Generic name | OSI-930 and erlotinib |
|---|---|
| Sponsor | Astellas Pharma Inc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OSI-930 and erlotinib CI brief — competitive landscape report
- OSI-930 and erlotinib updates RSS · CI watch RSS
- Astellas Pharma Inc portfolio CI
Frequently asked questions about OSI-930 and erlotinib
What is OSI-930 and erlotinib?
OSI-930 and erlotinib is a Small molecule drug developed by Astellas Pharma Inc.
Who makes OSI-930 and erlotinib?
OSI-930 and erlotinib is developed by Astellas Pharma Inc (see full Astellas Pharma Inc pipeline at /company/astellas).
What development phase is OSI-930 and erlotinib in?
OSI-930 and erlotinib is in Phase 1.
Related
- Manufacturer: Astellas Pharma Inc — full pipeline
- Compare: OSI-930 and erlotinib vs similar drugs
- Pricing: OSI-930 and erlotinib cost, discount & access